{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:52:19Z","timestamp":1768269139740,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.mayocp.2014.08.019","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T23:13:19Z","timestamp":1414624399000},"page":"1621-1635","source":"Crossref","is-referenced-by-count":66,"title":["Comparative Efficacy of Biologic Therapy in Biologic-Na\u00efve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"89","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushil Kumar","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell S.","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hassan Murad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2014.08.019_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.mayocp.2014.08.019_bib2","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/ibd.21488","article-title":"Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review","volume":"17","author":"Park","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"15","key":"10.1016\/j.mayocp.2014.08.019_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9317","key":"10.1016\/j.mayocp.2014.08.019_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.019_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.019_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn\u2019s disease","volume":"6","author":"Watanabe","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.019_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2014.08.019_bib8","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn\u2019s disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.mayocp.2014.08.019_bib9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.mayocp.2014.08.019_bib10","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2014.08.019_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.mayocp.2014.08.019_bib12","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.019_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.mayocp.2014.08.019_bib14","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/2012.jama.11228","article-title":"How to use an article reporting a multiple treatment comparison meta-analysis","volume":"308","author":"Mills","year":"2012","journal-title":"JAMA"},{"issue":"7387","key":"10.1016\/j.mayocp.2014.08.019_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.mayocp.2014.08.019_bib16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.mayocp.2014.08.019_bib17","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.019_bib18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2014.08.019_bib19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0016-5085(98)70439-1","article-title":"An evidence-based approach to gastroenterology therapy","volume":"114","author":"Schoenfeld","year":"1998","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.019_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"10.1016\/j.mayocp.2014.08.019_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.mayocp.2014.08.019_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.mayocp.2014.08.019_bib23","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stats Med"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.019_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.019_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.019_bib26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn\u2019s disease patients: a randomized placebo-controlled trial","volume":"130","author":"L\u00e9mann","year":"2006","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.mayocp.2014.08.019_bib27","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A\u00a0short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease","volume":"337","author":"Targan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.019_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn\u2019s disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.019_bib29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.mayocp.2014.08.019_bib30","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn\u2019s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.019_bib31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.mayocp.2014.08.019_bib32","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.019_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.019_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A\u00a0randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn\u2019s disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.019_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.019_bib36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A\u00a0randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn\u2019s disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2014.08.019_bib37","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"issue":"11-12","key":"10.1016\/j.mayocp.2014.08.019_bib38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a PEGylated Fab\u2019 fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn\u2019s disease: an exploratory study","volume":"20","author":"Winter","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2014.08.019_bib39","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"issue":"18","key":"10.1016\/j.mayocp.2014.08.019_bib40","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2014.08.019_bib41","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","article-title":"Long-term treatment of rectovaginal fistulas in Crohn\u2019s disease: response to infliximab in the ACCENT II Study","volume":"2","author":"Sands","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.019_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.019_bib43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/gutjnl-2011-300755","article-title":"Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial","volume":"61","author":"Van Assche","year":"2012","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.mayocp.2014.08.019_bib44","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0016-5085(14)61382-2","article-title":"Comparative efficacy of biologic therapy in patients with ulcerative colitis: a systematic review and indirect treatment comparison meta-analysis","volume":"146","author":"Singh","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2014.08.019_bib45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cgh.2013.06.010","article-title":"Comparative effectiveness of infliximab and adalimumab for Crohn\u2019s disease","volume":"12","author":"Osterman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619614007976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619614007976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T04:51:43Z","timestamp":1538110303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619614007976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0025619614007976"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2014.08.019","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}